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A B S T R A C T
The current chemotherapeutical treatment against alveolar echinococcosis relies exclusively on benzimidazoles,
which are not parasiticidal and can induce severe toxicity. There are no alternative treatment options. To
identify novel drugs with activity against Echinococcus multilocularis metacestodes, researchers have studied
potentially interesting drug targets (e.g. the parasite's energy metabolism), and/or adopted drug repurposing
approaches by undertaking whole organism screenings. We here focus on drug screening approaches, which
utilize an in vitro screening cascade that includes assessment of the drug-induced physical damage of metaces-
todes, the impact on metacestode viability and the viability of isolated parasite stem cells, structure-activity
relationship (SAR) analysis of compound derivatives, and the mode of action. Finally, once in vitro data are
indicative for a therapeutic window, the efficacy of selected compounds is assessed in experimentally infected
mice. Using this screening cascade, we found that the anti-malarial mefloquine was active against E. multi-
locularis metacestodes in vitro and in vivo. To shed more light into the mode of action of mefloquine, SAR analysis
on mefloquine analogues was performed. E. multilocularis ferritin was identified as a mefloquine-binding protein,
but its precise role as a drug target remains to be elucidated. In mice that were infected either intraperitoneally
with metacestodes or orally with eggs, oral treatment with mefloquine led to a significant reduction of parasite
growth compared to the standard treatment with albendazole. However, mefloquine was not acting para-
siticidally. Assessment of mefloquine plasma concentrations in treated mice showed that levels were reached
which are close to serum concentrations that are achieved in humans during long-term malaria prophylaxis.
Mefloquine might be applied in human AE patients as a salvage treatment. Future studies should focus on other
repurposed anti-infective compounds (MMV665807, niclosamide, atovaquone), which showed stronger in vitro
activity against E. multilocularis than mefloquine.
1. Introduction – alveolar echinococcosis (AE)
1.1. AE - why should we care?
Alveolar echinococcosis (AE) is caused by the cestode Echinococcus
multilocularis (small fox tapeworm). AE is the highest ranked foodborne
parasitic disease in Europe and is classified third on a global level
(Bouwknegt et al., 2018), despite relatively low case numbers in com-
parison to other parasitic diseases. In 2010, 18′451 new human cases of
AE were estimated (Torgerson et al., 2015), with the highest pre-
valences in Asia with up to 9.43% in Qinghai, China, and 6.4% in
Kyrgyz Alay district, Kyrgyzstan (Baumann et al., 2019; Bebezov et al.,
2018). In Western-Central Europe, the annual infection rate is com-
parably low with 0.3–3 per 1′000′000 inhabitants (Gottstein et al.,
2015a). However, due to the severity and fatality of the disease, human
AE has an annual global impact of more than 687′823 disability ad-
justed life years (DALYs) (Torgerson et al., 2015), which poses an un-
controlled health problem especially in developing and resource-poor
regions (Kern et al., 2017). Furthermore, AE is recognized as an
emerging disease in Europe, North America and Asia (Gottstein et al.,
2015a; Thompson, 2017; Trotz-Williams et al., 2017; Bebezov et al.,
2018; Robertson, 2018; Polish et al., 2020), and curative drug treat-
ments are still lacking (Lundström-Stadelmann et al., 2019).
1.2. E. multilocularis and AE – how we get infected
E. multilocularis is endemic in the Northern hemisphere and found
all over Central and Eastern Europe, Central and Eastern Asia, and
North America. The natural life cycle of E. multilocularis includes defi-
nitive hosts such as canids (foxes, dogs, and raccoon-dogs) and a variety
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Abbreviations
ABZ albendazole
AE alveolar echinococcosis
BMZ benzimidazole
DALYs disability adjusted life years
ELQ endochin-like quinolone
GL germinal layer
LL laminated layer
MBZ mebendazole
MD malate dismutation
MMV Medicines for Malaria Venture
SAR structure-activity relationship
TDH threonine dehydrogenase
Fig. 1. In vitro drug-screening pipeline to
identify novel compounds against E.
multilocularis.
The pipeline can be applied to screen drug
collections containing up to several hun-
dred molecules to identify compounds with
distinct activity against E. multilocularis
metacestodes. First, overview screenings
are performed on whole metacestodes by
measuring damage marker release in the
PGI-assay. Positive hits are confirmed, and
EC50 values calculated based on the same
assay. The parasiticidal potential is assessed
on metacestodes by a viability assay
(Alamar blue assay). Thereafter, toxicity on
various mammalian cell lines is assessed
(Alamar blue assay). The parasiticidal po-
tential is further confirmed by assessing the
viability of isolated GL cells (CellTiter Glo
assay). If all the above-mentioned tests are
indicative for a therapeutic window, more
in-depth studies concerning the mode of
action and SAR studies can optionally be
pursued. Finally, compounds are assessed in
experimentally infected mice. Figure
adapted from (Lundström-Stadelmann
et al., 2019).
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of mammalian intermediate hosts (mostly rodents, but accidently also
humans, captive monkeys, dogs, and others) (Romig et al., 2017). In-
termediate or accidental hosts get orally infected through parasite eggs
that are shed within the faeces of final hosts and contaminate the en-
vironment. Each egg contains a first larval stage, the oncosphere, which
is released in the intestinal lumen of the intermediate host. The onco-
sphere then migrates through the intestinal wall, reaches the blood-
stream and ends up primarily in the liver, where it develops into the
second larval stage, the metacestode, and thereby causes the disease
AE. In susceptible hosts, the metacestode undergoes unlimited asexual
proliferation by budding of parasite vesicles, and thus grows in-
filtratively into the surrounding host tissue. E. multilocularis metaces-
todes form cancer-like lumps, and can also form metastases at more
distant sites of the body. Eventually, AE results in severe organ dys-
function, mostly in the liver, but also in other infected organs. In nat-
ural hosts, but rarely in humans, brood capsules with protoscoleces are
formed within the metacestodes after several months. These represent
precursors of the next generation of tapeworms. To conclude the
parasite life cycle, ingestion of a naturally infected rodent by a final
host results in attachment of protoscoleces to the intestinal wall of the
final host, followed by the development of adult tapeworms (Romig
et al., 2017).
In human patients, AE is a chronic disease, which exhibits severe
symptoms that appear usually 10–15 years post-infection. It has many
pathological similarities with a slowly growing, malignant hepatic
tumor. The parasitic lesion gradually invades the liver tissue, vessels,
and bile ducts and may reach a size of up to 20 cm with a central
necrotic cavity (Kern et al., 2017). In the progressive stage of human
AE, non-specific symptoms such as abdominal pain, jaundice, choles-
tasis, hepatomegaly, fever, anaemia, weight loss, and pleural pain ap-
pear (Kern et al., 2017). Additionally, an AE diagnosis poses a con-
tinuously high psychological burden to patients (Schmidberger et al.,
2018; Nikendei et al., 2019). Finally, at an advanced stage, and if not
treated properly or if treatment fails, AE will lead to the death
(Lundström-Stadelmann et al., 2019).
It has been hypothesized that, at least in Switzerland, only a small
fraction of people exposed to infectious E. multilocularis eggs develop a
progressive form of the disease (Gottstein et al., 2015b). The reasons for
this are still unknown, but the immune system is crucial in determining
the final outcome of infection. Several studies reported on the rapid
development of AE in HIV patients (Sailer et al., 1997; Zingg et al.,
2004), and others have brought up the increased risk of occurrence and
progression of AE in immunosuppressed patients (Chauchet et al., 2014;
Gottstein et al., 2015b; Lachenmayer et al., 2019).
2. AE – current drugs and treatments
Invasive surgical resection of the whole parasite tissue represents
the only curative treatment of AE. However, this cannot be achieved at
later stages of infection, when the parasite has grown and spread highly
invasively (Grüner et al., 2017; Salm et al., 2019). Therefore, radical
surgery is only applied in 20%–50% of all human AE cases (Kern et al.,
2017). Surgery always has to be combined with temporal chemotherapy
and long-term monitoring to treat and follow-up eventual parasite re-
sidues (Kern et al., 2017). If such a complete surgical resection of the
parasite is not feasible, treatment relies exclusively on the benzimida-
zoles (BMZs) mebendazole (MBZ, 40–50 mg/kg body weight, three
daily doses) or albendazole (ABZ, 10–15 mg/kg body weight, two daily
doses) (Brunetti et al., 2010). The parasitostatic action of BMZs reduces,
in the best case, further growth of the parasite. The described mode of
action of BMZs involves the binding to beta-tubulin (resulting in the
inhibition of tubulin polymerization and all connected cellular pro-
cesses), a target which is expressed in the stem cells of E. multilocularis
metacestodes as an isoform with low affinity to these drugs (Brehm and
Koziol, 2014). Therefore, stem cells of E. multilocularis are more re-
sistant to BMZs than other cells of the parasite, and this leads, together
with the limited uptake and half-life of BMZs, to a parasitostatic rather
than parasiticidal effect. The consequence of this is that for the treat-
ment of AE, BMZs have to be taken life-long as parasite growth will
resume its growth upon treatment discontinuation. The multiple daily
dosages of BMZs in AE patients lead to problems in compliance, as well
as to side-effects (in 54.5% of patients from a study in Germany), in-
cluding severe adverse effects (described in 6.9% of German AE pa-
tients) leading to treatment discontinuation and no other options left
for further treatment (Grüner et al., 2017). Disease progression due to
treatment failure was described in up to 16% of German AE cases
(Grüner et al., 2017). In countries with lower access to good health
infrastructure, close monitoring of drug-levels might not be feasible,
and thus adverse effects and treatment failures might be more common
but remain unreported. All these shortcomings underline the urgency in
developing alternative chemotherapeutic options against AE.
3. Identification of novel drugs against alveolar echinococcosis
3.1. In vitro and in vivo drug testing models
Several years ago, markedly improved in vitro culture techniques for
E. multilocularis metacestodes and primary (stem) cells were made
available (Spiliotis et al., 2004, 2008). The in vitro grown metacestodes
exhibit the same morphological features as naturally grown metaces-
todes: each metacestode consists of a cluster of fluid-filled vesicles,
which are surrounded by three layers: the laminated layer (LL), the
tegument, and the germinal layer (GL). The acellular carbohydrate-rich
LL, which forms the outer surface, protects the parasite against host
reactions. The syncytial tegument is anchored to the interior surface of
the LL via microvilli-like protrusions termed microtriches, and is fol-
lowed by the GL, which is composed of connective tissue, muscle cells,
nerve cells, glycogen storage cells, and undifferentiated stem cells
(Koziol et al., 2014). These stem cells need to be killed to achieve a
parasiticidal effect upon drug treatment of the parasite (Brehm and
Koziol, 2014). Based on these in vitro grown E. multilocularis metaces-
todes, different drug-screening assays were developed, which produced
objective and quantifiable read-outs that were all combined in a
screening pipeline to identify active compounds from a collection of
diverse molecules (see Fig. 1) (Lundström-Stadelmann et al., 2019).
These include (i) PGI-assay (Stadelmann et al., 2010), with PGI release
as an indicator of physical impairment of metacestodes; (ii) Alamar blue
assay (Stadelmann et al., 2016), which measures loss of viability of
metacestodes; (iii) CellTiter Glo assay to assess ATP production and
thus viability of isolated parasite stem cells (Stadelmann et al., 2016);
(iv) electron microscopy to determine morphological/structural effects
(Stadelmann et al., 2016; Rufener et al., 2018a); in addition (v) Alamar
blue assay is performed on drug treated mammalian cell cultures to
determine a potential therapeutic window (Rufener et al., 2018a); and
(vi) structure-activity relationship (SAR) studies are carried out with
several derivatives from one compound (Rufener et al., 2018b), which
contribute to (vii) investigations on the mode of action (Rufener et al.,
2018a). Finally, if in vitro data are indicative for a therapeutic window,
(viii) the efficacy of selected compounds is assessed in experimentally
infected mice. Although not representing the exact natural intermediate
hosts, laboratory mice are very close to natural intermediate hosts of E.
multilocularis, and they allow to study the parasite in a controlled in vivo
setting. There are two murine models that are commonly applied: (i)
the secondary infection model, in which mice are intraperitoneally in-
fected with E. multilocularis metacestode suspension. This model re-
presents the advanced, disseminated and chronic stage of AE
(Stadelmann et al., 2016; Gorgas et al., 2017); (ii) the primary egg
infection model (Rufener et al., 2018b), in which mice are orally in-
fected by gavage of E. multilocularis eggs, representing the natural route
of infection and early parasite lesions.
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3.2. Drug development against AE
As in other fields of drug development, two basic approaches can be
followed to identify novel compounds with efficacy against AE: (i)
mechanism-/target-based screening (bottom-up approach), or (ii) phe-
notypic screening of whole organisms (top-down approach) (Geary
et al., 2015; Müller and Hemphill, 2016; Aulner et al., 2019). For target-
based screening, a valid molecular target in the parasite has to be
identified and validated, before specific inhibitors are designed and
screened. Even though this approach has not yet been successful in
bringing anti-parasitic drugs on the market, it is generally seen as the
more sophisticated approach. An essential prerequisite for the identi-
fication of novel targets is a profound knowledge of the parasite bio-
chemistry and its metabolic requirements. A recent publication by
Ritler et al. (2019) reported on the molecular footprint of E. multi-
locularis metacestodes, and by analysing the metabolic host-parasite
interface in vitro, a number of potentially targetable metabolic path-
ways were identified. An important finding was that not only the ubi-
quitous energy source glucose, but also the amino acid threonine, was
consumed by the parasite at high levels. Threonine consumption could
involve the catabolism of the amino acid through the threonine dehy-
drogenase (TDH), which is described in several other organisms, but is
inactive in humans (Edgar, 2002; Wang et al., 2009; Millerioux et al.,
2013), thus representing a potential target to be followed in the future.
In addition, Ritler et al. showed that final electron acceptors such as
succinate, acetate, and fumarate were released in by the metacestodes
at high amounts, which is strongly indicative that the malate dis-
mutation (MD) pathway is functionally active in these parasites
(McManus and Smyth, 1978). MD is found in helminths, marine in-
vertebrates, and euglenids, but is absent in mammals. It basically re-
presents an inversion of the TCA cycle, using rhodoquinone instead of
ubiquinone as an electron carrier (Tielens, 1994; Komuniecki and
Harris, 1995; Kita et al., 2003). The MD pathway allows for mi-
tochondrial energy generation under anaerobic conditions (Bryant,
1970; Tielens, 1994). As already primarily investigated in Echinococcus
protoscoleces and other helminths, the MD of E. multilocularis could
represent a viable drug target (Tielens, 1994; Matsumoto et al., 2008).
Recently, two studies reported on the successful inhibition of the
electron transfer chain in E. multilocularis GL cells and metacestodes by
atovaquone, buparvaquone, and the endochin-like quinolone ELQ-400
(Rufener et al., 2018a; Enkai et al., 2020). Thus, the respective target,
the complex III of the mitochondrial respiration chain, could be further
followed up with more selective inhibitors. In conclusion, the energy
metabolism of E. multilocularis is different from the mammalian one,
and this could offer different options for a targeted development of
novel drugs.
Phenotypic screening of whole organisms has so far been the ap-
proach which led to all anti-parasitic drugs on the market (Aulner et al.,
2019). For E. multilocularis and AE, the methods described in 3.1. can be
applied for such screenings (Lundström-Stadelmann et al., 2019). Due
to the fact that pharmaceutical companies have been increasingly re-
luctant to engage in preclinical drug development for AE, the focus is on
repurposing of already existing drugs or compound classes that are on
the market or being developed for other indications. Marketed drugs
have the highest potential for reaching AE patients responding poorly to
benzimidazoles, or with major side-effects, to apply them as salvage
treatment. Moreover, drug-repurposing also includes experimental
molecules that have proven activities against different indications, al-
beit their pharmacological profile is not completely described yet or not
suitable for clinical application in patients. Nevertheless, such drugs are
a promising starting point for screening approaches with limited re-
sources, and potentially allow to gain more insights about their possible
modes of action and thus potentially valuable targets where research
should be focused. Most studies on drug repurposing against AE eval-
uated an overall relatively small number of compounds, including anti-
cancer compounds (Naguleswaran et al., 2006; Gelmedin et al., 2008,
2010; Spicher et al., 2008a; Hübner et al., 2010; Hemer and Brehm,
2012; Schubert et al., 2014; Huang et al., 2018; Joekel et al., 2018;
Förster et al., 2019), anti-infective drugs (Reuter et al., 2003, 2006;
Stettler et al., 2003; Spicher et al., 2008b; Stadelmann et al., 2010,
2011; Küster et al., 2011, 2014a, 2014b, 2015; Rufener et al., 2018a,
2018b), immunotherapeutics (Emery et al., 1998; Pfister et al., 1989;
Godot et al., 2003; Boubaker et al., 2015; Wang et al., 2018; Jebbawi
et al), and natural products (Albani Clara and Elissondo María, 2014;
Albani et al., 2015; Yuan et al., 2016; Hizem et al., 2019). In the fol-
lowing sections, we will focus more on anti-infective drugs, and in
particular on the group of anti-malarials.
3.2.1. Repurposing of anti-infective drugs against AE
A plethora of anti-infective compounds were tested against E. mul-
tilocularis in rodent models and in vitro in the past (Lundström-
Stadelmann et al., 2019), including (i) BMZ (Siles-Lucas et al., 2018),
(ii) nitazoxanide (Stettler et al., 2003), (iii) amphotericin B and itra-
conazole (Reuter et al., 2003, 2006), (iv) inhibitors of the mitochon-
drial respiration chain (Enkai et al., 2020; Rufener et al., 2018a), and
(v) mefloquine (further discussed in chapter 4 and following).
However, to date only the (i) BMZ were shown to be active also
against human AE. More recent studies suggest to improve the ab-
sorption and oral bioavailability of these drugs by developing new
formulations such as BMZ salt formulations (Cirilli et al., 2017) or
nanocrystals (Pensel et al., 2018; Bakhtiar et al., 2019; Ullio Gamboa
et al., 2019). Two other drugs that reached clinical application against
AE over the last years are (ii) the broad-spectrum anti-parasitic nita-
zoxanide and (iii) the anti-fungal agent amphotericin B. However, they
were not further pursued due to low or no activity in humans, and also
pronounced side-effects (Kern et al., 2008; Tappe et al., 2009). (iv)
Inhibitors of the mitochondrial respiratory chain (i.e. buparvaquone,
atovaquone and the endochin-like quinolone ELQ-400) were identified
as highly active compounds in vitro (Rufener et al., 2018a; Enkai et al.,
2020). Atovaquone exhibited activity in the primary mouse infection
model against AE (Enkai et al., 2020), whereas buparvaquone was not
active in the secondary AE mouse infection model, presumably due to
the fast metabolization and short plasma half-life of buparvaquone
(Rufener et al., 2018a). Further analyses revealed that buparvaquone,
atovaquone, and most likely also ELQ-400, inhibit the mitochondrial
complex III in E. multilocularis (Rufener et al., 2018a; Enkai et al.,
2020). These inhibitors of the respiratory chain will have to be in-
vestigated further to determine whether they can be translated into a
promising treatment option against human AE.
4. Mefloquine
Mefloquine is an anti-malarial drug, which is structurally related to
quinine. Mefloquine is known to induce various side-effects, ranging
from diarrhea, nausea, and stomach pain, to more severe adverse re-
actions such as neurological and psychological disturbances (Tickell-
Painter et al., 2017). However, the high half-life of mefloquine allows
for less frequent dosing in malaria-prophylaxis, and thereby better pa-
tient compliance. For these reasons, the use of mefloquine is mostly
limited for the prevention and treatment of chloroquine-resistant ma-
laria and for prophylaxis in pregnant malaria patients, but mefloquine
is not recommended for patients with a previous history of psycholo-
gical disorders (Tickell-Painter et al., 2017).
Mefloquine is not only active against Plasmodium, but also against a
range of trematode species: it was shown to exhibit promising activity
against schistosomiasis in vitro and in mice (Keiser et al., 2009a;
Manneck et al., 2010; Panic et al., 2017), and against S. haematobium
infection in humans (Keiser et al., 2010; Basra et al., 2013), but did not
increase the efficacy of praziquantel when tested in humans with S.
haematobium infections (Keiser et al., 2014). In addition, mefloquine
was active against Opisthorchis viverrini in vitro and in hamsters (Keiser
et al., 2009b), but not in human patients (Soukhathammavong et al.,
B. Lundström-Stadelmann, et al. IJP: Drugs and Drug Resistance 13 (2020) 121–129
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2011). Against nematodes, mefloquine was active in vitro against adults
and microfilariae of Brugia patei and B. malayi (Walter et al., 1987),
against Onchocerca gutturosa (Townson et al., 1990), against micro-
filariae of Loa loa (Njouendou et al., 2018), and against Mansonella
perstans microfilariae (Njouendou et al., 2019). Overall, mefloquine
shows activity against a variety of helminth parasite species.
4.1. Activity of mefloquine against E. multilocularis metacestodes
Initially, mefloquine was tested against in vitro grown E. multi-
locularis metacestodes. After only 2–6 h of incubation of metacestodes
in 24 μM mefloquine, a strong detachment of the GL from the LL was
apparent as observed by light microscopy and scanning electron mi-
croscopy (Küster et al., 2011). Transmission electron microscopy con-
firmed these findings and demonstrated a time-dependent depletion of
glycogen storage cells in the GL, and loss of microtriches as well as of
the overall structural integrity of the parasite tissue. The PGI-assay
revealed that the effects on metacestodes were dose-dependent, with an
estimated EC50 for mefloquine of> 30 μM, and no difference was ob-
served between the (+)- and the (−) -erythro-enantiomers of me-
floquine ((Küster et al., 2011; Stadelmann et al., 2011), Table 1). The
IC50 against extracted E. multilocularis GL cells was calculated to be
13.8 μM in the CellTiter Glo assay ((Stadelmann et al., 2016), Table 1).
Further, mefloquine-treated metacestodes from in vitro cultures were
injected into Balb/c mice, to assess the viability of the parasite. In all 5
mice that had received E. multilocularis material pre-treated at 24 μM
mefloquine for 10 days in vitro, no parasite growth was observed after 5
months of incubation. In contrast, when the parasites were pre-treated
only at 12 μM mefloquine, the parasite recovered (Küster et al., 2011).
The minimal concentration to exert parasiticidal effects in vitro was
50 μM according to the Alamar Blue vesicle viability test ((Stadelmann
et al., 2016), Table 1). It was thereby proven that mefloquine has the
potential to act parasiticidally against E. multilocularis metacestodes,
although only at comparably high concentration.
Subsequently, mefloquine was tested in murine AE models for its
efficacy. In the secondary infection model, mefloquine, applied at
25 mg/kg twice per week during 8 weeks by intraperitoneal injection,
was as active as the standard ABZ treatment (200 mg/kg/day for 8
weeks (Küster et al., 2011)), but was not active when applied orally.
However, when applied orally at 100 mg/kg twice per week for a
duration of 12 weeks, mefloquine efficacy was similar to ABZ treatment
of treatment (Küster et al., 2015). The reduction in parasite burden was
hereby similar to 5 dosages of 200 mg/kg ABZ per week. At lower
dosages mefloquine was not active (Küster et al., 2015). When re-in-
jecting this parasite tissue into new mice, however, the parasite re-
grew, also from the highest dosed treatment group, implying that at a
treatment dose of 100 mg/kg twice per week, mefloquine was not fully
parasiticidal against E. multilocularis metacestodes (Küster et al., 2015).
In the primary (egg) infection model, treatment of mice with 100 mg/
kg mefloquine twice per week during 12 weeks reduced liver lesion
numbers, as assessed by visual inspection and confirmed by PCR
(Rufener et al., 2018b). The reduction was slightly lower when mice
were treated with 200 mg/kg ABZ for 5 days per week (Rufener et al.,
2018b). However, this result should be treated with caution, since in
that experiment the infection rate was relatively low. Taken together,
treatment with 100 mg/kg mefloquine twice per week led to a reduced
parasite mass/liver lesion number in mice, both in the primary as well
as the secondary infection model. Therefore, the mefloquine plasma
levels were assessed by HPLC and modelled in a standard two com-
partment pharmacokinetic model with first-order absorption from mice
treated with mefloquine at 100 mg/kg twice per week against primary
AE. An increase of mefloquine-levels over time was observed in the
plasma of all mice, with Cmin of 1.2 μg/mL and Cmax of 2.6 μg/mL being
reached to 90% after a treatment over 12 weeks (Rufener et al., 2018b).
These levels are close to concentrations achieved in humans during
long-term weekly dosage of 250 mg in malaria prophylaxis. Thus, this
already licenced drug could possibly be active in treatment against
human AE. However, data on cyst penetration and mefloquine con-
centrations reached in cysts, a major obstacle in the current AE treat-
ment, is lacking to date.
4.2. The mode of action of mefloquine against E. multilocularis
The mode of action of mefloquine in Plasmodium involves the in-
hibition of hemozoin formation, a crucial step in heme degradation, and
thereby leading to the accumulation of toxic heme (Egan et al., 1994).
Others have demonstrated the Plasmodium 80S ribosomal subunit, and
thus protein synthesis, to be targeted by mefloquine (Wong et al.,
2017). In adult schistosomes, a similar mode of action was described
(Corrêa Soares et al., 2009). In addition, the glycolytic enzyme enolase
was identified as a functional target in schistosomes (Manneck et al.,
2010). Further described targets are the PI3K/Akt/mTOR signalling
pathways in gastric and cervical cancer cells (Liu et al., 2016; Li et al.,
2017), inhibition of autophagy and induction of apoptosis in breast and
colorectal cancer cells (Sharma et al., 2012; Xu et al., 2018), gap
junction channels in neuroblastoma cells (Cruikshank et al., 2004),
cholinesterases of murine neurons (Lim and Go, 1985; McArdle et al.,
2005; Zhou et al., 2006), and non-receptor tyrosine-kinase 2 in rat
brains (Milatovic et al., 2011). Especially the latter of the here men-
tioned targets could play a role in the described neuropsychiatric side-
effects mefloquine may induce in some patients. To identify potential
mefloquine targets in E. multilocularis metacestodes, an affinity chro-
matography was performed, and E. multilocularis ferritin was identified
as a mefloquine-binding protein (Küster et al., 2015). It is notable that
enolase in schistosomes, haemoglobin in Plasmodium and schistosomes,
and ferritin in Echinococcus, are all metalloproteins and preferentially
affected by mefloquine. In vitro screening of a limited series of me-
floquine analogues against E. multilocularis metacestodes was carried
out to possibly identify derivatives with lower cytotoxicity and/or
higher anti-parasitic activity. However, thus far none of these analogues
exhibited improved activity compared to mefloquine (Rufener et al.,
2018b). Derivatives will now be used to specifically identify me-
floquine-interacting target proteins from E. multilocularis. Nevertheless,
the testing of analogues allowed for a limited SAR study, which re-
vealed that activity of mefloquine is highly dependent on the presence
of an amino group-containing residue at position 4 and the
Table 1
Shows the efficacy of mefloquine, MMV665807, and niclosamide against E. multilocularis metacestodes and GL cells. Given are the half-maximal concentrations of
metacestode damage (PGI-assay) and GL cell viability (CellTiter Glo assay), as well as the minimal inhibitory concentrations (MIC) for the metacestode viability assay
(Alamar blue assay). Values represent means from three independent experiments and respective standard deviations. Data concerning mefloquine and MMV665807
were previously published (Stadelmann et al., 2011, 2016). Data concerning niclosamide is unpublished (R. Rufener, Institute of Parasitology, Bern, Switzerland).
Mefloquine MMV665807 Niclosamide
Mean (μM) SD Mean (μM) SD Mean (μM) SD
Metacestode damage (EC50) > 30 – 1.2 1.6 0.085 0.031
Metacestode viability (MIC) 50 – 1.6 – 0.3 –
GL cell viability (IC50) 13.8 0.33 0.6 0.37 0.111 0.008
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trifluoromethyl residue on position 8 of the quinoline structure
(Rufener et al., 2018b). This is in line with the anti-malarial activity of
mefloquine and it implies that the mode of action in E. multilocularis
might be similar to the one against Plasmodium.
5. Repurposing of anti-malarial drugs against AE
Apart from mefloquine, several anti-malarials have been shown to
be efficacious against parasitic helminths (Panic et al., 2014), and some
of them were tested for their efficacy against E. multilocularis meta-
cestodes: artesunate and semi-synthetic derivatives were active in vitro,
but not in the murine AE model (Spicher et al., 2008b), synthetic
amino-ozonides were partially active against metacestodes in vitro
(Küster et al., 2014a), and atovaquone was efficacious in vitro and in
experimentally infected mice (Enkai et al., 2020). Stadelmann et al.
carried out in vitro screening of the Medicines for Malaria Venture
(MMV) malaria box, an open-source collection of 400 compounds with
proven in vitro activity against P. falciparum (Stadelmann et al., 2016).
A highly interesting drug candidate, MMV665807, was identified that
exhibited an EC50 against metacestodes of 1.2 μM (PGI assay). The IC50
for cultured Echinococcus GL cells was 0.6 μM (CellTiter Glo assay), and
the minimal concentration required for parasiticidal activity was
1.6 μM ((Stadelmann et al., 2016), and own, unpublished results,
Table 1). Thus, MMV665807 was more than 10 times more efficacious
in vitro than mefloquine. Unfortunately, when assessed in the secondary
infection model in mice, neither oral nor intraperitoneal application of
MMV665807 resulted in any reduction of metacestode burden
(Stadelmann et al., 2016). Possibly, novel formulations, which increase
the plasma levels of MMV665807 could lead to better in vivo efficacy.
MMV665807 is a salicylanilide-derivative, which is similar to the
commercially available niclosamide, an anthelmintic active against
adult stages of various tapeworms as well as experimentally promising
against Parkinsons disease, diabetes, viral and microbial infections, and
different types of cancer (Kadri et al., 2018; Haby et al., 2020).
Therefore, also the in vitro activity of niclosamide was compared to
MMV665807, and niclosamide showed an even better profile against E.
multilocularis metacestodes in vitro (Table 1). Niclosamide, however, is
poorly absorbed in vivo. Therefore, current studies involve the testing of
novel formulations of niclosamide against murine AE.
6. Conclusion
Novel - and most importantly - improved options for the che-
motherapeutical treatment of AE as an alternative to the currently ap-
plied BMZs are actively investigated. A major factor that has ac-
celerated the search for such compounds is the availability of efficient
and reliable culture methods for metacestodes as well as for isolated GL
cells. This has enabled researchers to carry out medium-throughput
screenings using assays such as the PGI, Alamar blue, and CellTiter Glo,
all assays that are relatively inexpensive, reliable, and easy to handle.
For neglected diseases in general, drug repurposing has identified anti-
malarials as important resources for potential drug candidates. Among
those, compounds that affect the mitochondrial complex III of the
electron transport chain have emerged as interesting drug candidates,
including atovaquone, and ELQ-400. In addition, in vitro and in vivo
studies have shown that mefloquine could be an interesting alternative
to be used in cases where BMZ toxicity is a major obstacle or patients
are not responding to BMZ therapy. While the use of mefloquine could
present neurological problems, derivatisation of this compound might
provide a solution. Further studies on the exact mode of action of me-
floquine and on cyst penetration could lead to insights that provide
patients with an additional treatment option.
The significant advances in our knowledge on Echinococcus biology
at the molecular level, especially the more recent studies on the ex-
change of metabolites at the host-parasite interface, has identified novel
drug targets, among them the TDH and MD pathways, which are both
absent in humans but are important as energy-generating mechanism in
these helminths. In the past, both pathways in Echinococcus have mainly
been studied from a biochemical perspective, but there are not many
studies that investigated the potential of MD with respect to che-
motherapy. Further studies will aim at targeting these pathways using
drugs that act specifically against components of this pathway. For
many compounds, a major problem has been that promising in vitro
efficacy cannot be translated into activity in vivo, a problem that could
be potentially overcome by generating chemically modified derivatives,
different drug formulations, or the use of pro-drugs with improved
pharmacokinetic profiles. Importantly, the recent findings on the effi-
cacy of atovaquone in the mouse model are promising. Whether this can
be translated to the situation in humans remains to be verified.
However, the major concern is funding. Even though compounds are
readily being made available from interested parties, drug-screening
efforts need to be financed. It is important to increase public awareness
about AE and its implications for our society. Only then it will be
possible to generate sufficient resources to actually carry out the re-
search that is necessary to properly evaluate chemotherapeutically
promising compound classes in the future.
Funding
This work was supported by the Swiss National Science Foundation
(310030_192072, and 31003A_179439), and the COST CM1307.
Declaration of competing interest
None.
References
Albani Clara, C.M., Elissondo María, C., 2014. Efficacy of albendazole in combination
with thymol against Echinococcus multilocularis protoscoleces and metacestodes.
Acta Trop. 140, 61–67. https://doi.org/10.1016/j.actatropica.2014.08.007.
Albani, C.M., Pensel, P.E., Elissondo, N., Gambino, G., Elissondo, M.C., 2015. In vivo
activity of albendazole in combination with thymol against Echinococcus multi-
locularis. Vet. Parasitol. 212, 193–199. https://doi.org/10.1016/j.vetpar.2015.06.
030.
Aulner, N., Danckaert, A., Ihm, J., Shum, D., Shorte, S.L., 2019. Next-generation phe-
notypic screening in early drug discovery for infectious diseases. Trends Parasitol. 35,
559–570. https://doi.org/10.1016/j.pt.2019.05.004.
Bakhtiar, N.M., Akbarzadeh, A., Casulli, A., Mahami-Oskouei, M., Ahmadpour, E., Nami,
S., Rostami, A., Spotin, A., 2019. Therapeutic efficacy of nanocompounds in the
treatment of cystic and alveolar echinococcoses: challenges and future prospects.
Parasitol. Res. https://doi.org/10.1007/s00436-019-06416-5.
Basra, A., Mombo-Ngoma, G., Melser, M.C., Diop, D.A., Würbel, H., Mackanga, J.-R.,
Fürstenau, M., Zoleko, R.M., Adegnika, A.A., Gonzalez, R., Menendez, C., Kremsner,
P.G., Ramharter, M., 2013. Efficacy of mefloquine intermittent preventive treatment
in pregnancy against Schistosoma haematobium infection in Gabon: a nested ran-
domized controlled assessor-blinded clinical trial. Clin. Infect. Dis. Off. Publ. Infect.
Dis. Soc. Am. 56, e68–75. https://doi.org/10.1093/cid/cis976.
Baumann, S., Shi, R., Liu, W., Bao, H., Schmidberger, J., Kratzer, W., Li, W., Barth, T.F.E.,
Baumann, S., Bloehdorn, J., Fischer, I., Graeter, T., Graf, N., Gruener, B., Henne-
Bruns, D., Hillenbrand, A., Kaltenbach, T., Kern, Peter, Kern, Petra, Klein, K., Kratzer,
W., Ehteshami, N., Schlingeloff, P., Schmidberger, J., Shi, R., Staehelin, Y., Theis, F.,
Verbitskiy, D., Zarour, G., the interdisciplinary Echinococcosis Working Group Ulm,
2019. Worldwide literature on epidemiology of human alveolar echinococcosis: a
systematic review of research published in the twenty-first century. Infection 47,
703–727. https://doi.org/10.1007/s15010-019-01325-2.
Bebezov, B., Mamashev, N., Umetaliev, T., Ziadinov, I., Craig, P.S., Joekel, D.E., Deplazes,
P., Grimm, F., Torgerson, P.R., 2018. Intense focus of alveolar echinococcosis, south
Kyrgyzstan. Emerg. Infect. Dis. 24, 1119–1122. https://doi.org/10.3201/eid2406.
161641.
Boubaker, G., Hemphill, A., Huber, C.O., Spiliotis, M., Babba, H., Gottstein, B., 2015.
Prevention and immunotherapy of secondary murine alveolar echinococcosis em-
ploying recombinant EmP29 antigen. PLoS Neglected Trop. Dis. 9, e0003795.
https://doi.org/10.1371/journal.pntd.0003795.
Bouwknegt, M., Devleesschauwer, B., Graham, H., Robertson, L.J., van der Giessen, J.W.,
The Euro-Fbp workshop participants, 2018. Prioritisation of food-borne parasites in
Europe, 2016. Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. 23.
https://doi.org/10.2807/1560-7917.ES.2018.23.9.17-00161.
Brehm, K., Koziol, U., 2014. On the importance of targeting parasite stem cells in anti-
echinococcosis drug development. Parasite Paris France 21, 72. https://doi.org/10.
1051/parasite/2014070.
B. Lundström-Stadelmann, et al. IJP: Drugs and Drug Resistance 13 (2020) 121–129
126
Brunetti, E., Kern, P., Vuitton, D.A., 2010. Expert consensus for the diagnosis and treat-
ment of cystic and alveolar echinococcosis in humans. Acta Trop. 114, 1–16. https://
doi.org/10.1016/j.actatropica.2009.11.001.
Bryant, C., 1970. Electron transport in parasitic helminths and protozoa. Adv. Parasitol. 8,
139–172.
Chauchet, A., Grenouillet, F., Knapp, J., Richou, C., Delabrousse, E., Dentan, C., Millon,
L., Di Martino, V., Contreras, R., Deconinck, E., Blagosklonov, O., Vuitton, D.A.,
Bresson-Hadni, S., FrancEchino Network, 2014. Increased incidence and character-
istics of alveolar echinococcosis in patients with immunosuppression-associated
conditions. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 59, 1095–1104. https://
doi.org/10.1093/cid/ciu520.
Cirilli, R., Guglielmi, P., Formica, F.R., Casulli, A., Carradori, S., 2017. The sodium salt of
the enantiomers of ricobendazole: preparation, solubility and chiroptical properties.
J. Pharmaceut. Biomed. Anal. 139, 1–7. https://doi.org/10.1016/j.jpba.2017.01.057.
Corrêa Soares, J.B.R., Menezes, D., Vannier-Santos, M.A., Ferreira-Pereira, A., Almeida,
G.T., Venancio, T.M., Verjovski-Almeida, S., Zishiri, V.K., Kuter, D., Hunter, R., Egan,
T.J., Oliveira, M.F., 2009. Interference with hemozoin formation represents an im-
portant mechanism of schistosomicidal action of antimalarial quinoline methanols.
PLoS Neglected Trop. Dis. 3, e477. https://doi.org/10.1371/journal.pntd.0000477.
Cruikshank, S.J., Hopperstad, M., Younger, M., Connors, B.W., Spray, D.C., Srinivas, M.,
2004. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc.
Natl. Acad. Sci. U. S. A 101, 12364–12369. https://doi.org/10.1073/pnas.
0402044101.
Edgar, A.J., 2002. The human L-threonine 3-dehydrogenase gene is an expressed pseu-
dogene. BMC Genet. 3, 18.
Egan, T.J., Ross, D.C., Adams, P.A., 1994. Quinoline anti-malarial drugs inhibit sponta-
neous formation of beta-haematin (malaria pigment). FEBS Lett. 352, 54–57.
Emery, I., Leclerc, C., Sengphommachanh, K., Vuitton, D.A., Liance, M., 1998. In vivo
treatment with recombinant IL-12 protects C57BL/6J mice against secondary al-
veolar echinococcosis. Parasite Immunol. 20, 81–91.
Enkai, S., Inaoka, D.K., Kouguchi, H., Irie, T., Yagi, K., Kita, K., 2020. Mitochondrial
complex III in larval stage of Echinococcus multilocularis as a potential chemother-
apeutic target and in vivo efficacy of atovaquone against primary hydatid cysts.
Parasitol. Int. 75, 102004. https://doi.org/10.1016/j.parint.2019.102004.
Förster, S., Koziol, U., Schäfer, T., Duvoisin, R., Cailliau, K., Vanderstraete, M., Dissous,
C., Brehm, K., 2019. The role of fibroblast growth factor signalling in Echinococcus
multilocularis development and host-parasite interaction. PLoS Neglected Trop. Dis.
13, e0006959. https://doi.org/10.1371/journal.pntd.0006959.
Geary, T.G., Sakanari, J.A., Caffrey, C.R., 2015. Anthelmintic drug discovery: into the
future. J. Parasitol. 101, 125–133. https://doi.org/10.1645/14-703.1.
Gelmedin, V., Caballero-Gamiz, R., Brehm, K., 2008. Characterization and inhibition of a
p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis:
antiparasitic activities of p38 MAPK inhibitors. Biochem. Pharmacol. 76, 1068–1081.
https://doi.org/10.1016/j.bcp.2008.08.020.
Gelmedin, V., Spiliotis, M., Brehm, K., 2010. Molecular characterisation of MEK1/2- and
MKK3/6-like mitogen-activated protein kinase kinases (MAPKK) from the fox tape-
worm Echinococcus multilocularis. Int. J. Parasitol. 40, 555–567. https://doi.org/10.
1016/j.ijpara.2009.10.009.
Godot, V., Harraga, S., Podoprigora, G., Liance, M., Bardonnet, K., Vuitton, D.A., 2003.
IFN alpha-2a protects mice against a helminth infection of the liver and modulates
immune responses. Gastroenterology 124, 1441–1450.
Gorgas, D., Marreros, N., Rufener, R., Hemphill, A., Lundström-Stadelmann, B., 2017. To
see or not to see: non-invasive imaging for improved readout of drug treatment trials
in the murine model of secondary alveolar echinococcosis. Parasitology 144,
937–944. https://doi.org/10.1017/S0031182017000051.
Gottstein, B., Stojkovic, M., Vuitton, D.A., Millon, L., Marcinkute, A., Deplazes, P., 2015a.
Threat of alveolar echinococcosis to public health - a challenge for Europe. Trends
Parasitol. https://doi.org/10.1016/j.pt.2015.06.001.
Gottstein, B., Wang, J., Boubaker, G., Marinova, I., Spiliotis, M., Müller, N., Hemphill, A.,
2015b. Susceptibility versus resistance in alveolar echinococcosis (larval infection
with Echinococcus multilocularis). Vet. Parasitol., Special Issue: Plenary Papers
Presented at the ESCCAP 2014 Scientific Meeting 213. pp. 103–109. https://doi.org/
10.1016/j.vetpar.2015.07.029.
Grüner, B., Kern, Petra, Mayer, B., Gräter, T., Hillenbrand, A., Barth, T.F.E., Muche, R.,
Henne-Bruns, D., Kratzer, W., Kern, Peter, 2017. Comprehensive diagnosis and
treatment of alveolar echinococcosis: a single-center, long-term observational study
of 312 patients in Germany. GMS Infect. Dis. 1–12. https://doi.org/10.3205/
id000027.
Haby, M.M., Sosa Leon, L.A., Luciañez, A., Nicholls, R.S., Reveiz, L., Donadeu, M., 2020.
Systematic review of the effectiveness of selected drugs for preventive chemotherapy
for Taenia solium taeniasis. PLoS Neglected Trop. Dis. 14, e0007873. https://doi.org/
10.1371/journal.pntd.0007873.
Hemer, S., Brehm, K., 2012. In vitro efficacy of the anticancer drug imatinib on
Echinococcus multilocularis larvae. Int. J. Antimicrob. Agents 40, 458–462. https://
doi.org/10.1016/j.ijantimicag.2012.07.007.
Hizem, A., Lundström-Stadelmann, B., M’rad, S., Souiai, S., Ben Jannet, H., Flamini, G.,
Ascrizzi, R., Ghedira, K., Babba, H., Hemphill, A., 2019. Activity of Thymus capitatus
essential oil components against in vitro cultured Echinococcus multilocularis me-
tacestodes and germinal layer cells. Parasitology 1–12. https://doi.org/10.1017/
S0031182019000295.
Huang, X., Wiehr, S., Wild, A.-M., Voßberg, P., Hoffmann, W., Grüner, B., Köhler, C.,
Soboslay, P.T., 2018. The effects of taxanes, vorinostat and doxorubicin on growth
and proliferation of Echinococcus multilocularis metacestodes assessed with mag-
netic resonance imaging and simultaneous positron emission tomography.
Oncotarget 9, 9073–9087. https://doi.org/10.18632/oncotarget.24142.
Hübner, C., Wiehr, S., Kocherscheidt, L., Wehrl, H., Pichler, B.J., Schmid, A., Kern, P.,
Soboslay, P.T., 2010. Effects of in vitro exposure of Echinococcus multilocularis
metacestodes to cytostatic drugs on in vivo growth and proliferation of the parasite.
Parasitol. Res. 107, 459–463. https://doi.org/10.1007/s00436-010-1892-0.
Jebbawi, F., Bellanger, A.-P., Lundström-Stadelmann, B., Rufener, R., Dosch, M., Beldi,
G., Millon, L., Gottstein, Bruno, B., Wang, J., Submitted for publication. Innate and
Adaptive Immunity Interactions via PD-1/PDL-1 Immune Checkpoint Blockade in
Murine Alveolar Echinococcosis.
Joekel, D.E., Lundström-Stadelmann, B., Müllhaupt, B., Hemphill, A., Deplazes, P., 2018.
Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echino-
coccosis in vitro and in a mouse model. Exp. Parasitol. 188, 65–72. https://doi.org/
10.1016/j.exppara.2018.04.002.
Kadri, H., Lambourne, O.A., Mehellou, Y., 2018. Niclosamide, a drug with many (Re)
purposes. ChemMedChem 13, 1088–1091. https://doi.org/10.1002/cmdc.
201800100.
Keiser, J., Chollet, J., Xiao, S.-H., Mei, J.-Y., Jiao, P.-Y., Utzinger, J., Tanner, M., 2009a.
Mefloquine–an aminoalcohol with promising antischistosomal properties in mice.
PLoS Neglected Trop. Dis. 3, e350. https://doi.org/10.1371/journal.pntd.0000350.
Keiser, J., N'Guessan, N.A., Adoubryn, K.D., Silué, K.D., Vounatsou, P., Hatz, C., Utzinger,
J., N'Goran, E.K., 2010. Efficacy and safety of mefloquine, artesunate, mefloquine-
artesunate, and praziquantel against Schistosoma haematobium: randomized, ex-
ploratory open-label trial. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 50,
1205–1213. https://doi.org/10.1086/651682.
Keiser, J., Odermatt, P., Tesana, S., 2009b. Dose-response relationships and tegumental
surface alterations in Opisthorchis viverrini following treatment with mefloquine in
vivo and in vitro. Parasitol. Res. 105, 261–266. https://doi.org/10.1007/s00436-
009-1395-z.
Keiser, J., Silué, K.D., Adiossan, L.K., N'Guessan, N.A., Monsan, N., Utzinger, J., N'Goran,
E.K., 2014. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-pra-
ziquantel against Schistosoma haematobium: a randomized, exploratory, open-label
trial. PLoS Neglected Trop. Dis. 8, e2975. https://doi.org/10.1371/journal.pntd.
0002975.
Kern, P., Menezes da Silva, A., Akhan, O., Müllhaupt, B., Vizcaychipi, K.A., Budke, C.,
Vuitton, D.A., 2017. The echinococcoses: diagnosis, clinical management and burden
of disease. Adv. Parasitol. 96, 259–369. https://doi.org/10.1016/bs.apar.2016.09.
006.
Kern, P.A., Abboud, P., Kern, W., Stich, T.A., Bresson-Hadni, S., Guerin, B., Buttenschoen,
K., Gruener, B., Reuter, S., Hemphill, A., 2008. Critical appraisal of nitazoxanide for
the treatment of alveolar echinococcosis. Am. J. Trop. Med. Hyg. 79, 119.
Kita, K., Nihei, C., Tomitsuka, E., 2003. Parasite mitochondria as drug target: diversity
and dynamic changes during the life cycle. Curr. Med. Chem. 10, 2535–2548.
Komuniecki, R., Harris, B.G., 1995. Carbohydrate and energy metabolism in helminths.
Biochemistry and Molecular Biology of Parasites Academic Press Inc, San Diego, CA
92101.
Koziol, U., Rauschendorfer, T., Zanon Rodríguez, L., Krohne, G., Brehm, K., 2014. The
unique stem cell system of the immortal larva of the human parasite Echinococcus
multilocularis. EvoDevo 5, 10. https://doi.org/10.1186/2041-9139-5-10.
Küster, T., Kriegel, N., Stadelmann, B., Wang, X., Dong, Y., Vennerstrom, J.L., Keiser, J.,
Hemphill, A., 2014a. Amino ozonides exhibit in vitro activity against Echinococcus
multilocularis metacestodes. Int. J. Antimicrob. Agents 43, 40–46. https://doi.org/
10.1016/j.ijantimicag.2013.09.012.
Küster, T., Stadelmann, B., Aeschbacher, D., Hemphill, A., 2014b. Activities of fenben-
dazole in comparison with albendazole against Echinococcus multilocularis meta-
cestodes in vitro and in a murine infection model. Int. J. Antimicrob. Agents 43,
335–342. https://doi.org/10.1016/j.ijantimicag.2014.01.013.
Küster, T., Stadelmann, B., Hermann, C., Scholl, S., Keiser, J., Hemphill, A., 2011. In vitro
and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis.
Antimicrob. Agents Chemother. 55, 713–721. https://doi.org/10.1128/AAC.
01392-10.
Küster, T., Stadelmann, B., Rufener, R., Risch, C., Müller, J., Hemphill, A., 2015. Oral
treatments of Echinococcus multilocularis-infected mice with the antimalarial drug
mefloquine that potentially interacts with parasite ferritin and cystatin. Int. J.
Antimicrob. Agents 46, 546–551. https://doi.org/10.1016/j.ijantimicag.2015.07.
016.
Lachenmayer, A., Gebbers, D., Gottstein, B., Candinas, D., Beldi, G., 2019. Elevated in-
cidence of alveolar echinococcosis in immunocompromised patients. Food
Waterborne Parasitol., e00060. https://doi.org/10.1016/j.fawpar.2019.e00060.
Li, H., Jiao, S., Li, X., Banu, H., Hamal, S., Wang, X., 2017. Therapeutic effects of anti-
biotic drug mefloquine against cervical cancer through impairing mitochondrial
function and inhibiting mTOR pathway. Can. J. Physiol. Pharmacol. 95, 43–50.
https://doi.org/10.1139/cjpp-2016-0124.
Lim, L.Y., Go, M.L., 1985. The anticholinesterase activity of mefloquine. Clin. Exp.
Pharmacol. Physiol. 12, 527–531.
Liu, Y., Chen, S., Xue, R., Zhao, J., Di, M., 2016. Mefloquine effectively targets gastric
cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling
pathway. Biochem. Biophys. Res. Commun. 470, 350–355. https://doi.org/10.1016/
j.bbrc.2016.01.046.
Lundström-Stadelmann, B., Rufener, R., Ritler, D., Zurbriggen, R., Hemphill, A., 2019.
The importance of being parasiticidal… an update on drug development for the
treatment of alveolar echinococcosis. Food Waterborne Parasitol. 15, e00040.
https://doi.org/10.1016/j.fawpar.2019.e00040.
Manneck, T., Haggenmüller, Y., Keiser, J., 2010. Morphological effects and tegumental
alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma
mansoni. Parasitology 137, 85–98. https://doi.org/10.1017/S0031182009990965.
Matsumoto, J., Sakamoto, K., Shinjyo, N., Kido, Y., Yamamoto, N., Yagi, K., Miyoshi, H.,
Nonaka, N., Katakura, K., Kita, K., Oku, Y., 2008. Anaerobic NADH-fumarate re-
ductase system is predominant in the respiratory chain of Echinococcus
B. Lundström-Stadelmann, et al. IJP: Drugs and Drug Resistance 13 (2020) 121–129
127
multilocularis, providing a novel target for the chemotherapy of alveolar echino-
coccosis. Antimicrob. Agents Chemother. 52, 164–170. https://doi.org/10.1128/
AAC.00378-07.
McArdle, J.J., Sellin, L.C., Coakley, K.M., Potian, J.G., Quinones-Lopez, M.C., Rosenfeld,
C.A., Sultatos, L.G., Hognason, K., 2005. Mefloquine inhibits cholinesterases at the
mouse neuromuscular junction. Neuropharmacology 49, 1132–1139. https://doi.
org/10.1016/j.neuropharm.2005.06.011.
McManus, D.P., Smyth, J.D., 1978. Differences in the chemical composition and carbo-
hydrate metabolism of Echinococcus granulosus (horse and sheep strains) and E.
multilocularis. Parasitology 77, 103–109.
Milatovic, D., Jenkins, J.W., Hood, J.E., Yu, Y., Rongzhu, L., Aschner, M., 2011.
Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase.
Neurotoxicology 32, 578–585. https://doi.org/10.1016/j.neuro.2011.01.001.
Millerioux, Y., Ebikeme, C., Biran, M., Morand, P., Bouyssou, G., Vincent, I.M., Mazet, M.,
Riviere, L., Franconi, J.-M., Burchmore, R.J.S., Moreau, P., Barrett, M.P., Bringaud,
F., 2013. The threonine degradation pathway of the Trypanosoma brucei procyclic
form: the main carbon source for lipid biosynthesis is under metabolic control. Mol.
Microbiol. 90, 114–129. https://doi.org/10.1111/mmi.12351.
Müller, J., Hemphill, A., 2016. Drug target identification in protozoan parasites. Expet
Opin. Drug Discov. 11, 815–824. https://doi.org/10.1080/17460441.2016.1195945.
Naguleswaran, A., Spicher, M., Vonlaufen, N., Ortega-Mora, L.M., Torgerson, P.,
Gottstein, B., Hemphill, A., 2006. In vitro metacestodicidal activities of genistein and
other isoflavones against Echinococcus multilocularis and Echinococcus granulosus.
Antimicrob. Agents Chemother. 50, 3770–3778. https://doi.org/10.1128/AAC.
00578-06.
Nikendei, C., Greinacher, A., Berkunova, A., Junghanss, T., Stojkovic, M., 2019.
Psychological burden and resilience factors in patients with Alveolar Echinococcosis -
a cross-sectional study. PLoS Neglected Trop. Dis. 13, e0007082. https://doi.org/10.
1371/journal.pntd.0007082.
Njouendou, A.J., Fombad, F.F., O'Neill, M., Zofou, D., Nutting, C., Ndongmo, P.C.,
Kengne-Ouafo, A.J., Geary, T.G., Mackenzie, C.D., Wanji, S., 2018. Heterogeneity in
the in vitro susceptibility of Loa loa microfilariae to drugs commonly used in para-
sitological infections. Parasites Vectors 11, 223. https://doi.org/10.1186/s13071-
018-2799-3.
Njouendou, A.J., Kien, C.A., Esum, M.E., Ritter, M., Chounna Ndongmo, W.P., Fombad,
F.F., Gandjui, N.V.T., Njiokou, F., Enyong, P., Pfarr, K., Turner, J., Layland, L.E.,
Hoerauf, A., Wanji, S., 2019. In vitro maintenance of Mansonella perstans micro-
filariae and its relevance for drug screening. Exp. Parasitol. 206, 107769. https://doi.
org/10.1016/j.exppara.2019.107769.
Panic, G., Duthaler, U., Speich, B., Keiser, J., 2014. Repurposing drugs for the treatment
and control of helminth infections. Int. J. Parasitol. Drugs Drug Resist. 4, 185–200.
https://doi.org/10.1016/j.ijpddr.2014.07.002.
Panic, G., Ruf, M.-T., Keiser, J., 2017. Immunohistochemical investigations of treatment
with Ro 13-3978, praziquantel, oxamniquine, and mefloquine in schistosoma man-
soni-infected mice. Antimicrob. Agents Chemother. 61. https://doi.org/10.1128/
AAC.01142-17.
Pensel, P., Paredes, A., Albani, C.M., Allemandi, D., Sanchez Bruni, S., Palma, S.D.,
Elissondo, M.C., 2018. Albendazole nanocrystals in experimental alveolar echino-
coccosis: enhanced chemoprophylactic and clinical efficacy in infected mice. Vet.
Parasitol. 251, 78–84. https://doi.org/10.1016/j.vetpar.2017.12.022.
Pfister, T., Schad, V., Frank, W., 1989. Interferon gamma in experimental echinococcosis.
J. Interferon Res. 9, S136.
Polish, L.B., Pritt, B., Barth, T.F.E., Gottstein, B., O'Connell, E.M., Gibson, P.C., 2020.
Echinococcus multilocularis: first European haplotype identified in the United States:
an emerging disease? Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. https://doi.org/
10.1093/cid/ciaa245.
Reuter, S., Manfras, B., Merkle, M., Härter, G., Kern, P., 2006. In vitro activities of itra-
conazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae.
Antimicrob. Agents Chemother. 50, 2966–2970. https://doi.org/10.1128/AAC.
00476-06.
Reuter, S., Merkle, M., Brehm, K., Kern, P., Manfras, B., 2003. Effect of amphotericin B on
larval growth of Echinococcus multilocularis. Antimicrob. Agents Chemother. 47,
620–625.
Ritler, D., Rufener, R., Li, J.V., Kämpfer, U., Müller, J., Bühr, C., Schürch, S., Lundström-
Stadelmann, B., 2019. In vitro metabolomic footprint of the Echinococcus multi-
locularis metacestode. Sci. Rep. 9, 19438. https://doi.org/10.1038/s41598-019-
56073-y.
Robertson, L.J., 2018. Parasites in food: from a neglected position to an emerging issue.
Adv. Food Nutr. Res. 86, 71–113. https://doi.org/10.1016/bs.afnr.2018.04.003.
Romig, T., Deplazes, P., Jenkins, D., Giraudoux, P., Massolo, A., Craig, P.S., Wassermann,
M., Takahashi, K., de la Rue, M., 2017. Ecology and life cycle patterns of echino-
coccus species. Adv. Parasitol. 95, 213–314. https://doi.org/10.1016/bs.apar.2016.
11.002.
Rufener, R., Dick, L., D'Ascoli, L., Ritler, D., Hizem, A., Wells, T.N.C., Hemphill, A.,
Lundström-Stadelmann, B., 2018a. Repurposing of an old drug: in vitro and in vivo
efficacies of buparvaquone against Echinococcus multilocularis. Int. J. Parasitol.
Drugs Drug Resist. 8, 440–450. https://doi.org/10.1016/j.ijpddr.2018.10.011.
Rufener, R., Ritler, D., Zielinski, J., Dick, L., da Silva, E.T., da Silva Araujo, A., Joekel,
D.E., Czock, D., Goepfert, C., Moraes, A.M., de Souza, M.V.N., Müller, J., Mevissen,
M., Hemphill, A., Lundström-Stadelmann, B., 2018b. Activity of mefloquine and
mefloquine derivatives against Echinococcus multilocularis. Int. J. Parasitol. Drugs
Drug Resist. 8, 331–340. https://doi.org/10.1016/j.ijpddr.2018.06.004.
Sailer, M., Soelder, B., Allerberger, F., Zaknun, D., Feichtinger, H., Gottstein, B., 1997.
Alveolar echinococcosis of the liver in a six-year-old girl with acquired im-
munodeficiency syndrome. J. Pediatr. 130, 320–323. https://doi.org/10.1016/
S0022-3476(97)70364-0.
Salm, L.A., Lachenmayer, A., Perrodin, S.F., Candinas, D., Beldi, G., 2019. Surgical
treatment strategies for hepatic alveolar echinococcosis. Food Waterborne Parasitol.
15, e00050. https://doi.org/10.1016/j.fawpar.2019.e00050.
Schmidberger, J., Weimer, H., Schlingeloff, P., Kratzer, W., Grüner, B., Echinococcosis
Working Group, Ulm, 2018. Health-related quality of life in patients with alveolar
echinococcosis: a cross-sectional study. Infection. https://doi.org/10.1007/s15010-
018-1219-0.
Schubert, A., Koziol, U., Cailliau, K., Vanderstraete, M., Dissous, C., Brehm, K., 2014.
Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase
EmPlk1. PLoS Neglected Trop. Dis. 8, e2870. https://doi.org/10.1371/journal.pntd.
0002870.
Sharma, N., Thomas, S., Golden, E.B., Hofman, F.M., Chen, T.C., Petasis, N.A., Schönthal,
A.H., Louie, S.G., 2012. Inhibition of autophagy and induction of breast cancer cell
death by mefloquine, an antimalarial agent. Canc. Lett. 326, 143–154. https://doi.
org/10.1016/j.canlet.2012.07.029.
Siles-Lucas, M., Casulli, A., Cirilli, R., Carmena, D., 2018. Progress in the pharmacological
treatment of human cystic and alveolar echinococcosis: compounds and therapeutic
targets. PLoS Neglected Trop. Dis. 12, e0006422. https://doi.org/10.1371/journal.
pntd.0006422.
Soukhathammavong, P., Odermatt, P., Sayasone, S., Vonghachack, Y., Vounatsou, P.,
Hatz, C., Akkhavong, K., Keiser, J., 2011. Efficacy and safety of mefloquine, artesu-
nate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with
Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet
Infect. Dis. 11, 110–118. https://doi.org/10.1016/S1473-3099(10)70250-4.
Spicher, M., Naguleswaran, A., Ortega-Mora, L.M., Müller, J., Gottstein, B., Hemphill, A.,
2008a. In vitro and in vivo effects of 2-methoxyestradiol, either alone or combined
with albendazole, against Echinococcus metacestodes. Exp. Parasitol. 119, 475–482.
https://doi.org/10.1016/j.exppara.2008.02.012.
Spicher, M., Roethlisberger, C., Lany, C., Stadelmann, B., Keiser, J., Ortega-Mora, L.M.,
Gottstein, B., Hemphill, A., 2008b. In vitro and in vivo treatments of echinococcus
protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
Antimicrob. Agents Chemother. 52, 3447–3450. https://doi.org/10.1128/AAC.
00553-08.
Spiliotis, M., Lechner, S., Tappe, D., Scheller, C., Krohne, G., Brehm, K., 2008. Transient
transfection of Echinococcus multilocularis primary cells and complete in vitro re-
generation of metacestode vesicles. Int. J. Parasitol. 38, 1025–1039. https://doi.org/
10.1016/j.ijpara.2007.11.002.
Spiliotis, M., Tappe, D., Sesterhenn, L., Brehm, K., 2004. Long-term in vitro cultivation of
Echinococcus multilocularis metacestodes under axenic conditions. Parasitol. Res. 92,
430–432. https://doi.org/10.1007/s00436-003-1046-8.
Stadelmann, B., Küster, T., Scholl, S., Barna, F., Kropf, C., Keiser, J., Boykin, D.W.,
Stephens, C.E., Hemphill, A., 2011. In vitro efficacy of dicationic compounds and
mefloquine enantiomers against Echinococcus multilocularis metacestodes.
Antimicrob. Agents Chemother. 55, 4866–4872. https://doi.org/10.1128/AAC.
00478-11.
Stadelmann, B., Rufener, R., Aeschbacher, D., Spiliotis, M., Gottstein, B., Hemphill, A.,
2016. Screening of the open source malaria box reveals an early lead compound for
the treatment of alveolar echinococcosis. PLoS Neglected Trop. Dis. 10, e0004535.
https://doi.org/10.1371/journal.pntd.0004535.
Stadelmann, B., Scholl, S., Müller, J., Hemphill, A., 2010. Application of an in vitro drug
screening assay based on the release of phosphoglucose isomerase to determine the
structure-activity relationship of thiazolides against Echinococcus multilocularis
metacestodes. J. Antimicrob. Chemother. 65, 512–519. https://doi.org/10.1093/jac/
dkp490.
Stettler, M., Fink, R., Walker, M., Gottstein, B., Geary, T.G., Rossignol, J.F., Hemphill, A.,
2003. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis
metacestodes. Antimicrob. Agents Chemother. 47, 467–474.
Tappe, D., Müller, A., Frosch, M., Stich, A., 2009. Limitations of amphotericin B and
nitazoxanide in the treatment of alveolar echinococcosis. Ann. Trop. Med. Parasitol.
103, 177–181. https://doi.org/10.1179/136485909X385036.
Thompson, R.C.A., 2017. Biology and systematics of echinococcus. Adv. Parasitol. 95,
65–109. https://doi.org/10.1016/bs.apar.2016.07.001.
Tickell-Painter, M., Maayan, N., Saunders, R., Pace, C., Sinclair, D., 2017. Mefloquine for
preventing malaria during travel to endemic areas. Cochrane Database Syst. Rev. 10,
CD006491. https://doi.org/10.1002/14651858.CD006491.pub4.
Tielens, A.G., 1994. Energy generation in parasitic helminths. Parasitol. Today Pers. Ed
10, 346–352.
Torgerson, P.R., Devleesschauwer, B., Praet, N., Speybroeck, N., Willingham, A.L.,
Kasuga, F., Rokni, M.B., Zhou, X.-N., Fèvre, E.M., Sripa, B., Gargouri, N., Fürst, T.,
Budke, C.M., Carabin, H., Kirk, M.D., Angulo, F.J., Havelaar, A., de Silva, N., 2015.
World health organization estimates of the global and regional disease burden of 11
foodborne parasitic diseases, 2010: a data synthesis. PLoS Med. 12, e1001920.
https://doi.org/10.1371/journal.pmed.1001920.
Townson, S., Dobinson, A.R., Townsend, J., Siemienska, J., Zea-Flores, G., 1990. The
effects of ivermectin used in combination with other known antiparasitic drugs on
adult Onchocerca gutturosa and O. volvulus in vitro. Trans. R. Soc. Trop. Med. Hyg.
84, 411–416. https://doi.org/10.1016/0035-9203(90)90340-k.
Trotz-Williams, L.A., Mercer, N.J., Walters, J.M., Wallace, D., Gottstein, B., Osterman-
Lind, E., Boggild, A.K., Peregrine, A.S., 2017. Public health follow-up of suspected
exposure to echinococcus multilocularis in southwestern ontario. Zoonoses Public
Health 64, 460–467. https://doi.org/10.1111/zph.12326.
Ullio Gamboa, G.V., Pensel, P.E., Elissondo, M.C., Sanchez Bruni, S.F., Benoit, J.-P.,
Palma, S.D., Allemandi, D.A., 2019. Albendazole-lipid nanocapsules: optimization,
characterization and chemoprophylactic efficacy in mice infected with Echinococcus
granulosus. Exp. Parasitol. 198, 79–86. https://doi.org/10.1016/j.exppara.2019.02.
002.
B. Lundström-Stadelmann, et al. IJP: Drugs and Drug Resistance 13 (2020) 121–129
128
Walter, R.D., Wittich, R.M., Kuhlow, F., 1987. Filaricidal effect of mefloquine on adults
and microfilariae of Brugia patei and Brugia malayi. Trop. Med. Parasitol. Off. Organ
Dtsch. Tropenmedizinische Ges. Dtsch. Ges. Tech. Zusammenarbeit GTZ 38, 55–56.
Wang, J., Alexander, P., Wu, L., Hammer, R., Cleaver, O., McKnight, S.L., 2009.
Dependence of mouse embryonic stem cells on threonine catabolism. Science 325,
435–439. https://doi.org/10.1126/science.1173288.
Wang, J., Jebbawi, F., Bellanger, A.-P., Beldi, G., Millon, L., Gottstein, B., 2018.
Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint
blockade in mice. Parasite Immunol. 40, e12596. https://doi.org/10.1111/pim.
12596.
Wong, W., Bai, X.-C., Sleebs, B.E., Triglia, T., Brown, A., Thompson, J.K., Jackson, K.E.,
Hanssen, E., Marapana, D.S., Fernandez, I.S., Ralph, S.A., Cowman, A.F., Scheres,
S.H.W., Baum, J., 2017. Mefloquine targets the Plasmodium falciparum 80S ribosome
to inhibit protein synthesis. Nat. Microbiol. 2, 17031. https://doi.org/10.1038/
nmicrobiol.2017.31.
Xu, X., Wang, J., Han, K., Li, S., Xu, F., Yang, Y., 2018. Antimalarial drug mefloquine
inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer
cells. Canc. Sci. 109, 1220–1229. https://doi.org/10.1111/cas.13540.
Yuan, M., Luo, Y., Xin, Q., Gao, H., Zhang, G., Jing, T., 2016. Efficacy of osthole for
Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo. Vet.
Parasitol. 226, 38–43. https://doi.org/10.1016/j.vetpar.2016.05.016.
Zhou, C., Xiao, C., McArdle, J.J., Ye, J.H., 2006. Mefloquine enhances nigral gamma-
aminobutyric acid release via inhibition of cholinesterase. J. Pharmacol. Exp.
Therapeut. 317, 1155–1160. https://doi.org/10.1124/jpet.106.101923.
Zingg, W., Renner-Schneiter, E.C., Pauli-Magnus, C., Renner, E.L., van Overbeck, J.,
Schläpfer, E., Weber, M., Weber, R., Opravil, M., Gottstein, B., Speck, R.F., Swiss HIV
Cohort Study, 2004. Alveolar echinococcosis of the liver in an adult with human
immunodeficiency virus type-1 infection. Infection 32, 299–302.
B. Lundström-Stadelmann, et al. IJP: Drugs and Drug Resistance 13 (2020) 121–129
129
